Early Access — free while we kick the tires
EdgarHawk

Russo Rene

PRESIDENT AND CEO

Director Officer
1 filing analyzed · 1 company · Latest 2025-06-18

Companies

Company Buys Sells Direction
Xilio Therapeutics, Inc. XLO 1 0 Net buying

Activity

June 2025
high
Buy
36,289 shares
$24,680
Significance 6/10

XLO CEO Rene Russo buys 36,289 shares at $0.68 while stock down 55.4% from 52-week high; company unprofitable.

CEO Rene Russo purchased 36,289 shares at $0.68, increasing his holdings by 14.8% to 281,172 shares total. This purchase occurred at a significant distance below the 52-week high of $20.72, and the stock has declined 24.9% over the preceding 30 days. The company is deeply unprofitable, reporting a net loss of $13,265,000.00 against quarterly revenue of $2,930,000.00, indicating substantial cash burn with minimal revenue generation. The magnitude of the purchase—14.8% incremental stake increase—at a depressed price level relative to recent history warrants examination of whether this reflects conviction or execution of a predetermined plan, especially given the company's negative net income trajectory.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access